Active Proliferative Lupus Nephritis When Add-On Belimumab or Voclosporin Has Not Achieved Renal Targets
Clinical Scenario
This protocol addresses active proliferative lupus nephritis in patients whose glomerular filtration rate remains preserved and who do not have cellular crescents, fibrinoid necrosis, or severe interstitial inflammation — yet have not attained an adequate renal response despite escalation with add-on combination therapy.
Previous Step: Goals Not Reached
The preceding treatment step involved adding belimumab or voclosporin for patients with an inadequate response or flare who were not initially receiving combination therapy. That step aimed to achieve at least a 50% reduction in proteinuria at 6 months, proteinuria below 500–700 mg/day at 12 months, and maintenance of glomerular filtration rate within 10% of baseline. Failure to meet those targets triggers escalation to this next-line protocol.
Next-Line Treatment Approach
In refractory active proliferative lupus nephritis of this type, a targeted biologic agent directed at specific immune cells is the next intervention to consider. The complete evidence-based regimen — including agent selection, sequencing, and monitoring guidance — is available in the full protocol.
Treatment Targets
- Proteinuria below 500–700 mg/day
- Glomerular filtration rate within 10% from baseline
References
DOI: 10.1136/ard-2023-224762
- Patients with active proliferative lupus nephritis should receive low-dose (EuroLupus) intravenous cyclophosphamide (1a/A) or mycophenolate (1a/A) and glucocorticoids (pulses of intravenous methylprednisolone followed by lower oral doses); combination therapy with belimumab (either with cyclophosphamide or mycophenolate (1b/A)) or calcineurin inhibitors (especially voclosporin or tacrolimus, combined with mycophenolate, 1b/A) should be considered.
- In patients with organ-threatening or life-threatening disease, intravenous cyclophosphamide (2b/C) should be considered; in refractory cases, rituximab (2b/C) may be considered.
- Following the choice of initial treatment, renal response should be monitored according to the 2019 EULAR/ERA-EDTA targets (reduction in proteinuria ≥25% and 50% at 3 and 6 months, respectively, and below 500–700 mg/day at 12 months, all with GFR within 10% from baseline).
View source ↗